Marta Melgosa Hijosa *

Autora invitada por SIIC

TRATAMIENTO ANTICIPADO CON GANCICLOVIR ORAL EN TRANSPLANTE RENAL PEDIATRICO

El trabajo defiende la utilidad del tratamiento anticipado con ganciclovir oral guiado por la monitorización de la antigenemia en sangre frente a la profilaxis continua en la prevención de la enfermedad por citomegalovirus en niños con transplante renal.

*Marta Melgosa Hijosa
describe para SIIC los aspectos relevantes de su trabajo
PREEMPTIVE TREATMENT WITH ORAL GANCICLOVIR FOR PEDIATRIC RENAL TRANSPLANTATION
Institución principal de la investigación
*Servicio de Nefrología Infantil Hospital "La Paz" Madrid, España, Madrid, España
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1. Patel R, Snydman DR, Rubin RH, Ho M, Pescovitz M, Martin M, Paya CV (1996) Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 61:1279-1289.
2. Snydman DR (1994) Cytomegalovirus prophylaxis strategies in high-risk transplantation. Transpl Proc 26 (suppl 1):20-26.
3. Turgeon N, Fishman JA, Basgoz N, Tolkoff-Rubin NE, Doran M, Cosimi AB, Rubin RH (1998) Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. Transplantation 66:1780-1786.
4. Noble S, Faulds D (1998) Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 56:115-146.
5. Kusne S, Grossi P, Irish W, St George K, Rinaldo CH, Rakela J, Fung J (1999) Cytomegalovirus pp65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 68: 1125-1131.
6. Hibberd PL, Tolkoff-Rubin NE, Conti D. (1995) Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody- positive renal transplant recipients. Ann Intern Med 123:18-25.
7. Filler G, Lampe D, von Bredow MA, Lappenberg-Pelzer M, Rocher S, Strehlau J, Ehrich HH. (1998) Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics. Pediatr Nephrol 12 :6-9 .
8. Pescovitz MD,Brook B, Filo RS (1996) Pharmacokinetics of oral ganciclovir in pediatric renal transplant recipients (abstract). Abstracts of the 15th annual meeting of the American Society of Transplant Physicians, Dallas, Texas, May 26-30, 1996.Transplantation 62(12):703-953.
9. Frenkel LM, Capparelli EV, Dankner WM, Xu J, Smith IL, Ballow A, Culnane M, Read JS, Thompson M, Mohan KM, Shaver A, Robinson CA, Stempien MJ, Burchett SK, Melvin AJ, Borkowsky W, Petru A, Kovacs A, Yogev R, Goldsmith J, McFarland EJ, Spector SA for the Pediatric AIDS Clinical Trial Group (2000) Oral ganciclovir in children: pharmakocinetics, safety , tolerance and antiviral effects. J Infect Dis 182: 1616-1624.
10. Akposso K, Rondeau E, Haymann JP, Peraldi MN, Marlin C, Sraer JD (1997) Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection. Transplantation 63 :974-976.